CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Cronos Group Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.25+0.04 (+1.25%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- 16.3
- Dividend yield
- –
Cronos Group Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cannabis flower | $133.06M | $118.87M | $108.48M | $98.13M | $98.10M | $93.73M | $87.91M | $82.03M | $73.11M | $66.47M | $62.07M | $60.11M | 74.3% | +35.6% |
| Cannabis extracts | $45.96M | $40.55M | $37.70M | $33.52M | $31.35M | $30.05M | $29.17M | $28.65M | $28.13M | $26.00M | $24.57M | $24.82M | 25.7% | +46.6% |
| Other | $69.00K | $120.00K | $411.00K | $708.00K | $842.00K | $809.00K | $535.00K | $547.00K | $528.00K | $572.00K | $602.00K | $428.00K | 0.0% | -91.8% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | $105.11M | $95.55M | $90.33M | $82.07M | $83.00M | $83.70M | $82.44M | $80.72M | $75.39M | $69.14M | $64.70M | $61.67M | 58.7% | +26.6% |
| Israel | $52.36M | $46.72M | $41.80M | $37.76M | $33.67M | $31.18M | $28.37M | $25.54M | $23.95M | $22.49M | $21.13M | $23.30M | 29.2% | +55.5% |
| Other countries | $21.62M | $17.27M | $14.46M | $12.53M | $13.61M | $9.71M | $6.81M | $4.97M | $2.43M | $1.41M | $1.41M | – | 12.1% | +58.8% |
From the segment and revenue-disaggregation notes of Cronos's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.